[ad_1]
The Ipsen group achieved a net turnover of more than 2.5 billion euros, representing a growth of 3% of its turnover in 2020.
Ipsen inaugurated its first regional office in the Middle East and Africa (MEA), headquartered in Dubai, to launch direct operations and bring innovative treatments to address unmet medical needs covering oncology, rare diseases and neuroscience in the region.
The inauguration of the Ipsen regional headquarters in the Al Jalila Foundation building in Dubai Healthcare City was attended by Dr Amin Hussain Al Amiri, Deputy Assistant Secretary of the Health Regulation Sector at the Ministry of Health and de la Prévention (MoHAP), Raja Rabia, Consul General of France in Dubai and the Northern Emirates, Dr Abdulkareem Sultan Al Olama, CEO of the Al Jalila Foundation, Professor Humaid Al Shamsi, President of the Emirates Oncology Society , representatives of the medical community and leaders of Ipsen.
Al Amiri said, “The UAE has emerged as a global pharmaceutical hub led by an outstanding healthcare and business infrastructure, and a strong legislative environment that supports healthcare companies that are innovative and meet international standards. Ipsen’s commitment to invest in the UAE and the region, and its decision to open its regional headquarters here is a welcome step that further underscores our country’s rich heritage in facilitating regional expansion. multinational companies. We look forward to innovative therapies from Ipsen that will help the healthcare community to further ensure the well-being of our communities. “
In 2020, the Ipsen group achieved net sales of over 2.5 billion euros, i.e. 3% growth in sales. The company continued to increase its R&D investments to reach 15.6% of its net sales and also made significant progress in building a rare disease franchise for the next decade.
Rabia said, “The UAE and France have a strong and long-standing relationship spanning culture, business, education, healthcare and more. Over the years, French companies have contributed to the economy and taken advantage of the opportunities offered by the country both nationally and to develop in regional markets. We congratulate Ipsen on opening its new regional headquarters in the United Arab Emirates and look forward to the positive impact this creates on the lives of patients as we continue to strengthen the friendship between our nations and build on the strong bilateral relations. “
Tackling life-threatening and underserved diseases with transformative medicines, Ipsen’s areas of expertise include neuroendocrine tumors, which are the second most common gastrointestinal tumor after colorectal cancer1; prostate cancer, breast cancer, spasticity and renal and hepatocellular carcinoma, among others.
Khaled Elrefae, Head for Ipsen, Middle East and Africa Specialty Care Operations said: “The opening of our new office in Dubai is an important milestone for our company. We look forward to creating value through our global innovation in oncology, rare diseases and neuroscience, as we strive to contribute to the health and well-being of the people of the UAE and the region, in particular at a time when health care is a top priority. . “
Journalist
[ad_2]
